AstraZeneca : Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer -March 27, 2024 at 03:09 am EDT
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations Approval based on CAPItello-291 results which showed...